Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Launches ADDPLAN® DF

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
An innovative software for optimizing dose selection in phase 2 trials.

Aptiv Solutions has announced the release of ADDPLAN® DF, an innovative software that designs, simulates, and analyzes Phase 2 dose finding studies to make them more efficient and effective.

ADDPLAN® DF is the latest product in the ADDPLAN® family that includes a series of products for adaptive confirmatory trials.

ADDPLAN® DF is a fully-validated design and analysis tool based on MCP-Mod methodology (a combination of Multiple Comparison Procedures and Modeling) and covers dose finding designs for establishing Proof of Concept and determining the optimum target dose to select for Phase 3 trials.

This tool will enable drug developers to remove a number of the uncertainties inherent in Phase 2 dose finding trials and improve critical decisions on dose-selection, which will directly impact the probability of success in Phase 3.

Currently half of Phase 3 trials fail, in part because of poor dose selection in Phase 2. Regulators, pharmaceutical companies and industry groups recognize that more robust Phase 2 studies are required to improve dose selection and this is the stimulus driving the development of ADDPLAN® DF.

“The consequences of improving dose selection should be measured in terms of the success rates of subsequent Phase 3 trials,” says Professor Andy Grieve, Senior Vice President, Clinical Trial Methodology for Aptiv Solutions and co-author, with Tobias Mielke and Parvin Fardipour, of a new white paper on the critical importance of dose finding trials.

Professor Grieve continued, “The business value of improving dose selection can amount to billions of dollars across a product portfolio and importantly deliver an increased number of novel medicines to patients.”

There has been a recent increase in the adoption of innovative designs in exploratory phase trials stimulated by vocal support from the FDA and EMA. “Getting it right at Phase 2” has been a rallying call from both regulators and industry for some time and the availability of ADDPLAN® DF will significantly help to achieve this objective.

In July, ADDPLAN® DF was pre-released in beta version to a top 5 pharma company that served as the prime development partner for the software. Two additional large pharma customers have also received the software as founding members of the ADDPLAN® DF Consortium announced earlier this year. The software will be available for purchase by other interested stakeholders in mid-October.

“Among the many advantages we see with ADDPLAN® DF,” says Professor Grieve, “is its adaptive analysis and modeling capability. Using the design engine, the optimal allocation rates for a robust dose-estimation can be calculated. The simulation engine allows the verification of characteristics of the chosen design, and the analysis engine enables data analysis using different multiple comparison procedures, modeling approaches and the combined MCP-Mod approach. This creates the optimum method to select the dose for confirmatory Phase 3 studies.”

The benefits of ADDPLAN® DF are applicable to mid-size and large pharmaceutical companies taking novel products through Phase 3, as well as biotech companies looking to increase the value of their early stage assets and to partner at Phase 2.

A further application is in medical device development where different strengths of a specific stimulus need to be evaluated.

This release of ADDPLAN® DF is the first in a series of novel methodologies for use in Phase 2 clinical trials. Subsequent versions will be released that deliver additional benefits to this critical phase of exploratory development.

The white paper titled ‘ADDPLAN® DF - An Advanced Tool for Optimizing Dose Selection in Exploratory Drug Development’ is available at http://www.aptivsolutions.com/addplan-df-landing-page/.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Aptiv Solutions Growing: Opens New Office in North Carolina
New office is located at 4505 Emperor Boulevard in the Imperial Center.
Monday, December 10, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!